We determined placental tissue levels, production rates, and secretion rates of isoprostanes for placentas obtained from women with normal pregnancies and women with preeclampsia, a hypertensive disorder of pregnancy. Isoprostanes are markers of oxidative stress that exert biological actions such as vasoconstriction. Placental tissue was rinsed and immediately frozen in liquid nitrogen to determine tissue levels of total and free isoprostane. Placental tissue pieces were also incubated in serum-free DMEM for 48 h at 37°C in 95% air/5% CO 2 to determine production rates. Isolated placental cotyledons were perfused for the determination of secretion rates. All samples were analyzed by EIA for isoprostane using an antibody specific for 8-Iso-PGF 2 (15-F 2t -IsoP). In addition, medium samples were analyzed for malondialdehyde (MDA), a breakdown product of lipid peroxidation. We found that tissue levels of free isoprostane and total isoprostane (free plus esterified forms) were significantly higher for preeclamptic placentas than for normal placentas. Concentrations of isoprostane and MDA in the medium increased progressively during 48 h of incubation of placental explants. At 48 h of incubation, the mean concentrations of both isoprostane and MDA were significantly higher for the placentas from preeclamptic women than for the placentas from normal pregnant women. Concentrations of MDA were highly correlated with those of isoprostane. Induction of oxidative stress with xanthine plus xanthine oxidase increased placental production of isoprostane by normal tissue to a level similar to that of preeclamptic tissue. Placental secretion of isoprostane was eightfold greater toward the maternal side of the placenta than toward the fetal side, and was increased sixfold on the maternal side and twofold on the fetal side by inducing oxidative stress with t-butyl hydroperoxide. This study presents new information that isoprostanes are formed and secreted by the human placenta and provides convincing evidence that oxidative stress and lipid peroxidation are abnormally increased in placentas of preeclamptic women.-Walsh, S. W., Vaughan, J. E., Wang, Y., Roberts, L. J., II. Placental isoprostane is significantly increased in preeclampsia. FASEB
Preeclampsia is one of the most significant health problems of human pregnancy. It is a leading cause of fetal growth restriction, premature birth, and low birth weight babies. Preeclampsia is a hypertensive disorder of pregnancy characterized by increased vasoconstriction leading to maternal hypertension and reduced blood flow to organs and tissues, including the kidneys, uterus, and placenta. Increased platelet aggregation, disseminated intravascular coagulation, endothelial cell dysfunction, proteinuria, and edema are other abnormalities associated with preeclampsia. Severe preeclampsia can lead to eclampsia, which is characterized by maternal convulsions thought to be caused by cerebral vasoconstriction. Despite considerable research on preeclampsia, the only treatment at present is removal of the fetus and placenta. The cause of preeclampsia is still not known.
Isoprostanes are recently discovered prostaglandinlike products formed in vivo by free radical-catalyzed nonenzymatic peroxidation of arachidonic acid (1) . Isoprostanes are considered to be accurate markers of oxidative stress and endogenous lipid peroxidation (2) (3) (4) (5) . They are formed in situ, esterified in phospholipids, and then released in free form, presumably by phospholipases (6) . Isoprostanes are carried in the circulation bound to lipoproteins.
The isoprostanes have been proposed as markers of oxidative damage, but they also exert biological actions. Isoprostanes are potent vasoconstrictors in the kidney, lung, heart, brain and placenta (1, (7) (8) (9) (10) . Isoprostanes also stimulate IP3 and mitogenesis in vascular smooth muscle cells and induce the release of endothelin from endothelial cells (11, 12) . Some investigators report increased maternal circulating levels of endothelin in preeclampsia, which is thought to result from endothelial cell dysfunction (13, 14) . The biological actions of isoprostanes suggest that they could contribute to abnormalities of preeclampsia such as hypertension, endothelial cell dysfunction, renal vasoconstriction, placental vasoconstriction, and cerebral vasospasm of eclampsia.
Circulating and urinary levels of the F2-isoprostanes are high in patients with pathologies involving oxidative stress (15, 16) . Inhibition of the antioxidant enzyme copper-zinc superoxide dismutase (CuZn SOD) results in increased plasma levels of isoprostane (17) . In this regard, our previous finding that Cu-Zn SOD activity is decreased in placentas of preeclamptic women (18) suggests that placental isoprostane production would be increased in preeclampsia. The recent finding that maternal serum levels of free isoprostane are significantly higher in preeclampsia than in normal pregnancy (19) might be explained by increased secretion of placentally derived isoprostanes.
In the following study, we determined whether 1) the human placenta produces isoprostanes; 2) placental production and tissue levels of isoprostanes are higher in preeclampsia than normal pregnancy; 3) the human placenta secretes isoprostanes; and 4) oxidative stress stimulates placental production and secretion of isoprostanes. As an indicator of isoprostanes, we measured 8-Iso prostaglandin F 2␣ (8-Iso-PGF 2 ), which is now referred to as 15-F 2t -IsoP according to the nomenclature system approved by the Eicosanoid Nomenclature Committee (20) . We hypothesized that preeclamptic placentas would be characterized by significantly elevated levels of isoprostanes.
MATERIALS AND METHODS
Placentas were obtained immediately after delivery from normal (nϭ25) and preeclamptic (nϭ17) women delivering at the MCV Main Hospital. Institutional approval to conduct this study was granted by the Committee for the Conduct of Human Research. Normal pregnant patients had maternal blood pressures Յ 110/70 mmHg, no proteinuria, and no other complications. Preeclamptic patients had maternal blood pressures of 140/90 mmHg or higher, with proteinuria (Ͼ300 mg/24 h) on two separate readings at least 6 h apart. Preeclamptic patients also had pathological edema. There was no difference in the age of the preeclamptic patients vs. the normal patients (24.8Ϯ1.6 years vs. 22.3Ϯ1.3 years, respectively, PϾ0.1). The preeclamptic patients weighed significantly more than the normal patients (227.6Ϯ15.2 lb vs. 162.1Ϯ6.5 lb, PϽ0.001), and delivered earlier (36.1Ϯ1.0 wk vs. 39.4Ϯ0.3 wk of gestation, PϽ0.01). Babies born to the preeclamptic women weighed less than babies born to normal pregnant women (2716Ϯ256 g vs. 3225Ϯ123 g, PϽ0.05) and placental weights were less, although the difference in placental weight did not reach statistical significance (596Ϯ63 g vs. 684Ϯ49 g, PϾ0.1). There were six cesarean sections in the preeclamptic group and five in the normal group.
Extraction and hydrolysis of isoprostane from phospholipids in placental tissue
Placentas were obtained immediately after delivery from 13 women with preeclampsia and 12 women with normal pregnancy. Placental tissue pieces were initially separated by sterile dissection from different cotyledons, excluding chorionic and basal plates, rinsed with saline, and snap frozen in liquid nitrogen. The tissue pieces were stored in a freezer at Ϫ80°C. At the time of assay, 1 g of tissue was homogenized in 1.0 ml phosphate-buffered saline (PBS). Samples were extracted with 2.0 ml ethanol containing 0.005% butylated hydroxytoluene (BHT) to prevent oxidation during processing and with 5000 cpm of 3 H-PGF 2␣ to determine recovery of 15-F 2t -IsoP. Samples were centrifuged and the supernatants were split into two aliquots of 1.5 ml each. To one of the aliquots, 8.5 ml ultrapure H 2 O was added and the samples were acidified to below pH 4.0 to determine free 15-F 2t -IsoP. To the other aliquot, 1.5 ml of 15% potassium hydroxide (KOH) was added to determine total 15-F 2t -IsoP by base hydrolysis. These samples were incubated at 40°C for 1 h under nitrogen. Seven milliliters of ultrapure H 2 O was then added and the samples were acidified to below pH 4.0. All samples were purified by Sep-Pak C-18 cartridges before analysis by enzyme immunoassay (EIA).
Whole placental villi incubation
Placental tissues from seven preeclamptic women and seven normal pregnant women were incubated as described previously and validated (21, 22) . Briefly, placental tissue was gently separated by sterile dissection from different cotyledons, excluding chorionic and basal plates, minced with scalpel blades, and washed repeatedly with 0.9% sodium chloride to remove blood from the intervillous space. Whole villous tissue (350 mg/well) was incubated in 6-well 35 mm polystyrene tissue culture dishes in 7 ml of serum-free Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Inc. BLR, Grand Island, N.Y.) for 48 h at 37°C in an incubator gassed with air and 5% CO 2 (CH/P Tri Gas Processor incubator, Forma Scientific, Inc., Marietta, Ohio). Placental tissues were incubated in duplicate for each treatment. Medium samples were collected after 48 h and stored at Ϫ20°C. The placental tissue from each well was collected and frozen at Ϫ80°C for protein analysis.
Protein assay
Tissue protein concentrations were measured by the Coomassie blue dye binding method. Coomassie Plus protein assay reagent was purchased from Pierce Chemical Company (Rockford, Ill.). Bovine serum albumin was diluted in PBS for the standard curve.
Isolated human placental cotyledon perfusion
This methodology was used as described previously and validated (23, 24) . Placentas were obtained from six normal pregnant women. A chorionic plate artery leading to a single placental cotyledon and a chorionic plate vein draining the cotyledon were catheterized and perfusion was begun immediately. Krebs-Ringer bicarbonate (KRB) buffer gassed with 95% O 2 , 5% CO 2 and warmed to 37°C was used for perfusion. The composition of the KRB buffer was 125 mmol/l NaCl, 4.5 mmol/l KCl, 0.2 mmol/l Na 2 HPO 4 , 0.7 mmol/l NaH 2 PO 4 , 2.5 mmol/l CaCl 2 , 1.0 mmol/l MgSO 4 , 4.4 mmol/l glucose (80 mg%), 29.8 mEq/l NaHCO 3 . The placenta was placed in a water-jacketed perfusion chamber warmed to 37°C by a Haake constant temperature circulating water bath (Haake model D1L, Fisher Scientific Co., Pittsburgh, Pa.). To continuously monitor the perfusion pressure, the fetal arterial catheter was connected to a pressure transducer connected to a Transbridge TBM 4 transducer amplifier connected to a MP100WS data acquisition workstation (World Precision Instruments, Inc., Sarasota, Fla.). A Macintosh computer was used with AcqKnowledge waveform data analysis software (World Precision Instruments). The fetal side of the cotyledon was perfused at a rate of 2-4 ml/min to adjust the starting fetal side perfusion pressure to ϳ30 mmHg. The intervillous space on the maternal side of the cotyledon was perfused at a rate of 6 -7 ml/min by placing a butterfly needle attached to a catheter underneath the basal plate. Two Masterflex multichannel pumps were used for perfusion (Cole-Parmer Instrument Co., Chicago, Ill.). Treatment perfusion solutions were perfused for 20 min periods. Maternal and fetal effluent samples were collected during the last 5 min of each perfusion period and the effluent flow rates were recorded. Five milliliters of each sample were evaporated under vacuum centrifugation (SpeedVac Concentrator, Savant Instruments, Holbrook, N.Y.) and then reconstituted with ultrapure water to 0.5 ml. Samples were stored at Ϫ20°C. Oxygen consumption and carbon dioxide production were calculated to verify viability of the placental cotyledon. After each experiment, Crystal Violet dye was injected into the fetal arterial catheter in order to verify the cotyledon that was perfused. Placental secretion rates were calculated by multiplying the concentrations in either the fetal or maternal effluent by their respective effluent perfusion flow rates. Placental vascular resistance was calculated by dividing the chorionic plate arteriovenous pressure difference by the fetal effluent flow rate.
Isoprostane EIA
Isoprostane was measured by a commercially available EIA kit (Cayman Chemical, Ann Arbor, Mich.). The antibody was highly specific for 15-F 2t -IsoP (8-Iso PGF 2 ). The range of the standard curve was from 3.9 to 500 pg/ml. Samples were assayed at 50 l after a 1:10 or 1:20 dilution. The samples were read at 420 nm in a 96-well Spectra Microplate Autoreader (Tecan, Research Triangle park, N.C.). Serial sample dilutions were parallel to the standard curve. Within-and between-assay variations were Ͻ 10%. Analysis of 15-F 2t -IsoP by EIA was confirmed by gas chromatography-mass spectrophotometry (GC-MS). The correlation coefficient for medium samples analyzed by EIA vs. GC-MS was r ϭ 0.969.
Malondialdehyde (MDA) assay
Lipid peroxides were estimated by an improved analysis of malondialdehyde for human body fluids (25) . A sample size of 200 l was used. Tetramethoxypropane was used to generate MDA for the standard curve. BHT was added to prevent oxidation during the heating step with thiobarbituric acid. The n-butanol extracts of standards and samples were pipetted into 96-well microplates and the difference in absorption at 530 nm and 570 nm was measured in a spectrophotometer (Spectra Microplate Autoreader, Tecan). Serially diluted samples were parallel to the standard curve and within-and between-assay variations were Ͻ 10%.
Statistical analysis
Normally distributed data were analyzed by the unpaired t test or analysis of variance (random complete block), and nonnormally distributed data by the Mann-Whitney Rank Sum
RESULTS
Placental tissue levels of 15-F 2t -IsoP were significantly higher for women with preeclampsia than for nor- Figure 1 . Placental tissue levels of free 15-F 2t -IsoP (upper panel) and total 15-F 2t -IsoP (lower panel) for placentas obtained from women with normal pregnancies (nϭ12) or women with preeclampsia (nϭ13). One gram of placental tissue was homogenized in phosphate-buffered saline and then extracted with ethanol for the determination of the amount of free 15-F 2t -IsoP. For total 15-F 2t -IsoP, the ethanol extract was subjected to base hydrolysis with 15% KOH. Samples were purified by Sep-Pak C-18 cartridges before analysis by EIA. Preeclamptic placental tissue contained significantly more free 15-F 2t -IsoP and more total 15-F 2t -IsoP (free plus esterified isoprostane) than normal placental tissue. a, Significantly higher than normal, P Ͻ 0.01, b, significantly higher than normal, P Ͻ 0.05. Data represent mean Ϯ se. (Fig. 1,  PϽ0.01) . Levels for esterified 15-F 2t -IsoP averaged 602 Ϯ 107 pg/g for preeclamptic tissue and 411 Ϯ 80 pg/g for normal tissue (PϽ0.2). Tissue levels of total 15-F 2t -IsoP averaged 1038 Ϯ 142 pg/g for preeclamptic pregnancy and 669 Ϯ 84 pg/g for normal pregnancy (Fig. 1, PϽ0.05 ). Tissue levels of 15-F 2t -IsoP were not affected by the mode of delivery (PϾ0.9).
Release of 15-F 2t -IsoP from placental explants in culture was predominantly free 15-F 2t -IsoP (93%), with a smaller amount representing 15-F 2t -IsoP still esterified in phospholipids (7%). Placental production of free 15-F 2t -IsoP was significantly higher for women with preeclampsia than for normally pregnant women. Figure 2 shows representative time courses of the concentrations of free 15-F 2t -IsoP in the medium of placental explants from a woman with normal pregnancy and a woman with preeclampsia. Concentrations of 15-F 2t -IsoP increased progressively during the 48 h incubation period. After 48 h of incubation, the average concentrations of free 15-F 2t -IsoP for placental explants averaged 15.8 Ϯ 2.7 ng/mg protein for the preeclamptic group (nϭ7), but only 6.5 Ϯ 0.6 ng/mg protein for the normal group (nϭ7) (PϽ0.01).
To determine whether oxidative stress would stimulate the production of 15-F 2t -IsoP, tissue explants from a normal placenta were incubated for 48 h with or without xanthine (X, 0.5 mM) plus xanthine oxidase (XO, 0.005 units/ml). Xanthine oxidase generates the superoxide anion during enzymatic conversion of xanthine to uric acid. The X ϩ XO treatment increased free 15-F 2t -IsoP production by explants from the normal patient to a rate that was equivalent to that of explants from preeclamptic patients (Fig. 3) . After 24 h of incubation, the concentration for control explants was 6.3 ng/mg protein and 14.1 ng/mg protein for the X ϩ XOstimulated explants. After 48 h, the levels were 10.6 ng/mg for control and 19.7 ng/mg for X ϩ XO.
The placental production rate of lipid peroxides, as estimated by MDA, was significantly higher for placental explants from preeclamptic women than for placental explants from normal pregnant women. Concentrations of MDA increased progressively for both preeclamptic and normal groups during 48 h of incubation similar to concentrations of 15-F 2t -IsoP (Fig. 4) . After 48 h, the concentrations of MDA averaged 6.0 Ϯ 1.2 mol/mg protein for explants from preeclamptic women (nϭ7) and 2.2 Ϯ 0.4 mol/mg protein for explants from normal pregnant women (nϭ7) (PϽ0.01). The concentrations of MDA in the medium were highly correlated with the concentrations of 15-F 2t -IsoP (rϭ0.978).
Free 15-F 2t -IsoP was secreted by isolated placental cotyledons of normal placentas into the maternal and fetal effluents, but the secretion rate into the maternal effluent was significantly higher than the rate into the fetal effluent (Fig. 5) . The secretion rate toward the maternal side of the placental cotyledon was 1.03 Ϯ 0.49 ng/min as compared to the A chorionic plate artery and a chorionic plate vein serving a single vascular cotyledonary unit were catheterized. The cotyledon was perfused on the fetal side via the arterial catheter with KRB buffer at a rate of 2-4 ml/min. The maternal side of the cotyledon was perfused at a rate of 6 -7 ml/min by placing a butterfly needle attached to a catheter underneath the basal plate. The cotyledonary unit was placed in a water-jacketed perfusion chamber warmed to 37°C by a Haake constant-temperature circulating water bath. After a 30 min equilibration period, 5 ml effluent samples were collected from the fetal and maternal sides. The effluent samples were concentrated under vacuum centrifugation and reconstituted with ultrapure water to 0.5 ml for analysis of 15-F 2t -IsoP by EIA. The isolated placental cotyledon secreted free 15-F 2t -IsoP into both the maternal and fetal effluents, but the secretion rate toward the maternal side averaged ϳeightfold higher than toward the fetal side. a, Significantly higher than fetal side, P Ͻ 0.01. secretion rate toward the fetal side of 0.13 Ϯ 0.02 ng/min (PϽ0.01, nϭ6) . To determine whether 15-F 2t -IsoP secretion could be stimulated acutely and could be correlated with placental perfusion pressure and vascular resistance, isolated cotyledons of normal placentas were perfused with control buffer or t-butyl hydroperoxide (100 mol/l) for 20 min periods (nϭ6). Compared to the initial control perfusion (C-1), perfusion with t-butyl hydroperoxide (Px) significantly increased the secretion rate of free 15-F 2t -IsoP on the maternal side of the placental cotyledon by sixfold (1.03Ϯ0.49 vs. 6.48Ϯ2.87 ng/ min, PϽ0.05), and on the fetal side by almost twofold (0.133Ϯ0.023 vs. 0.213Ϯ0.041 ng/min, PϽ0.05) (Fig. 6) . Secretion rates returned to control levels when t-butyl hydroperoxide was discontinued. Perfusion with t-butyl hydroperoxide also significantly increased perfusion pressure of the placental cotyledon. Compared to the initial control, perfusion pressure increased from 30.4 Ϯ 1.6 to 46.8 Ϯ 3.2 mmHg (PϽ0.01). Increases in the maternal and fetal secretion rates of 15-F 2t -IsoP were significantly and positively correlated with the increase in perfusion pressure, r ϭ 0.544 and r ϭ 0.547, respectively (PϽ0.05). Vascular resistance was also significantly increased by perfusion with t-butyl hydroperoxide (12.7Ϯ1.0 for C-1 vs. 24.5Ϯ4.0 mmHgϮmin/ml for Px, PϽ0.01). The increases in perfusion pressure and vascular resistance returned to control levels after discontinuation of t-butyl hydroperoxide.
DISCUSSION
These data represent the first report of tissue levels, production rates, and secretion rates of isoprostane for the human placenta. The human placenta contains, produces, and secretes isoprostane. Both free 15-F 2t -IsoP and total 15-F 2t -IsoP tissue levels were significantly higher for placentas obtained from women with preeclampsia than from women with normal pregnancies. The increased amount of free 15-F 2t -IsoP in the placentas of preeclamptic women indicates an increase in the conversion of isoprostane from the esterified form to the free form, which would then be available for secretion into the mater- Figure 6 . Placental secretion of free 15-F 2t -IsoP was stimulated by inducing oxidative stress with t-butyl hydroperoxide. Placental cotyledons of placentas from normal pregnant women (nϭ6) were perfused sequentially for 20 min periods with KRB buffer (C-1), t-butyl hydroperoxide (100 mol/l), and KRB buffer (C-2). Effluent samples were collected during the last 5 min of each perfusion period and analyzed for free 15-F 2t -IsoP. Perfusion with t-butyl hydroperoxide significantly stimulated secretion of 15-F 2t -IsoP on both maternal and fetal sides of the placenta, but the magnitude of increase was considerably greater on the maternal side (sixfold) vs. the magnitude on the fetal side (twofold). After perfusion with t-butyl hydroperoxide, the maternal and fetal secretion rates of 15-F 2t -IsoP returned to baseline. Perfusion of the cotyledon with t-butyl hydroperoxide also increased perfusion pressure. The increase in perfusion pressure for each cotyledon correlated with the increases in the maternal and fetal secretion rates of 15-F 2t -IsoP. a, Significantly higher than C-1 and C-2, P Ͻ 0.01, b, significantly higher than C-1 and C-2, P Ͻ 0.05. nal and fetal circulations. The increase in free isoprostane in preeclampsia may result from an increase in the activity of placental phospholipase A 2 , which is increased in preeclampsia (26) .
Placental tissue explants produced isoprostane progressively during a 48 h incubation period. Concentrations of 15-F 2t -IsoP in the medium at 48 h of incubation were 2.4-fold higher for preeclamptic tissue explants than for normal tissue explants. Placentas of preeclamptic women are characterized by an increase in oxidative stress (22, 27) . It was therefore of interest to determine whether normal placental tissue exposed to oxidative stress would be stimulated to produce isoprostane. We found that placental explants from a normal placenta exposed to the superoxide anion generated by xanthine plus xanthine oxidase produced 15-F 2t -IsoP at a rate equivalent to that of placental explants from preeclamptic women. This suggests that the increase in isoprostane in preeclampsia occurs because of oxidative stress.
To further study the relationship between oxidative stress and isoprostane in the human placenta, we also measured MDA, a breakdown product of oxidized lipids and a commonly used indicator of lipid peroxidation. Concentrations of MDA in the medium increased in a progressive manner during 48 h of incubation in a pattern similar to that observed for 15-F 2t -IsoP. After 48 h, the medium concentrations of MDA were 2.7-fold higher for the placental explants from preeclamptic women than for the placental explants from normal pregnant women. Concentrations of MDA in the medium were highly correlated with 15-F 2t -IsoP. The correlation coefficient 'r' was 0.978, demonstrating an extremely close association between placental lipid peroxidation and the production of isoprostane.
We used the isolated perfused placental cotyledon model to determine whether the human placenta secretes isoprostane. 15-F 2t -IsoP was secreted into both the maternal and fetal effluents of the placental cotyledon, but the secretion rate toward the maternal side of the cotyledon was eightfold greater than the secretion rate toward the fetal side. Barden et al. (19) have reported that the concentrations of free isoprostane are significantly higher in the maternal circulation in women with preeclampsia than normally pregnant women. Our data suggest that the increase in circulating levels of free isoprostane in women with preeclampsia could originate from placental secretion.
To determine whether placental secretion of isoprostane was rapidly responsive to changes in oxidative stress, we perfused placental cotyledons for 20 min periods with control buffer, then with t-butyl hydroperoxide to induce oxidative stress, and then with control buffer again. We previously demonstrated that perfusion of the isolated placental cotyledon, with t-butyl hydroperoxide leads to a rapid increase in oxidative stress as evidenced by placental secretion of lipid peroxides (28) . Perfusion with t-butyl hydroperoxide led to a rapid increase in the maternal and fetal secretion rates of 15-F 2t -IsoP, with most of the isoprostane being secreted toward the maternal side. Perfusion with t-butyl hydroperoxide also caused an increase in the perfusion pressure of the cotyledon that was correlated with the secretion of 15-F 2t -IsoP. Recently, 15-F 2t -IsoP was demonstrated to cause vasoconstriction in the isolated perfused placental cotyledon (10) . These data suggest that increased placental production of isoprostane could be a cause of increased placental vasoconstriction in preeclampsia.
In summary, we found that 1) the human placenta contains, produces and secretes 15-F 2t -IsoP; 2) the production rate of free 15-F 2t -IsoP by placental explants and tissue levels of both free and total 15-F 2t -IsoP are significantly higher for placentas obtained from women with preeclampsia than from women with normal pregnancies; 3) the isolated placental cotyledon secretes 15-F 2t -IsoP, but the secretion rate toward the maternal side is eightfold greater than toward the fetal side; 4) oxidative stress induced by xanthine plus xanthine oxidase or t-butyl hydroperoxide stimulates production and secretion of 15-F 2t -IsoP, which is correlated with placental vasoconstriction. We also found that production by placental explants of malondialdehyde, a breakdown product of lipid peroxides, is significantly higher for placentas from preeclamptic women than for placentas from normal pregnant women, and that MDA is highly correlated with 15-F 2t -IsoP. These data suggest that elevated placental levels of isoprostane could contribute to placental vasoconstriction in preeclampsia and that placental secretion of isoprostane into the maternal circulation could contribute to vasoconstriction in maternal vascular beds.
